Stock ARDMQ ARADIGM CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

Aradigm Corporation Share Price

Equities

ARDMQ

US0385054004

Biotechnology & Medical Research

Delayed OTC Markets
Other stock markets
 		5-day change 1st Jan Change
- USD -.--% Intraday chart for Aradigm Corporation +6.73% -25.81%
2020 Aradigm Corporation Went Out of Business CI
2020 Modified Combined Liquidation Plan and Discosure Statement Approved for Aradigm Corporation CI

Financials

Sales 2016 195K 15.35M Sales 2017 14.46M 1.14B Capitalization 97.3M 7.66B
Net income 2016 -32M -2.52B Net income 2017 -10M -787M EV / Sales 2016 73.3 x
Net cash position 2016 9.37M 738M Net Debt 2017 7.91M 623M EV / Sales 2017 7.27 x
P/E ratio 2016
-0.72 x
P/E ratio 2017
-9.3 x
Employees -
Yield 2016 *
-
Yield 2017
-
Free-Float 60.28%
More Fundamentals * Assessed data

Chart Aradigm Corporation

Dynamic Chart

Latest news about Aradigm Corporation

Aradigm Corporation Went Out of Business CI
Modified Combined Liquidation Plan and Discosure Statement Approved for Aradigm Corporation CI
Revised Disclosure Statement Conditionally Approved for Aradigm Corporation CI
Combined Liquidation Plan and Disclosure Statement Filed by Aradigm Corporation CI
Grifols, S.A. completed the acquisition of Assets and Intellectual Property of Lipoquin, Free Ciprofloxacin, Apulmiq from Aradigm Corporation (OTCPK:ARDM.Q). CI
Motion for Asset Sale Approved for Aradigm Corporation CI
Bidding Procedure Approved for Aradigm Corporation CI
Motion for Asset Sale Filed by Aradigm Corporation CI
Grifols, S.A. entered into an asset purchase agreement to acquire Assets and Intellectual Property of Lipoquin, Free Ciprofloxacin, Apulmiq from Aradigm Corporation (OTCPK:ARDM.Q) for $6.3 million. CI
Second Motion for Exclusivity Period Extension Approved For Aradigm Corporation CI
Aradigm Corporation Announces Withdrawal of European Marketing Authorization Application for Linhaliq CI
Aradigm Corporation Receives Feedback Following an Oral Explanation with the European Medicines Agency CI
Motion for Exclusivity Period Extension Approved For Aradigm Corporation CI
First Motion for Exclusivity Period Extension Filed by Aradigm Corporation CI
DIP Financing Approved for Aradigm Corporation CI
More news

Press releases Aradigm Corporation

ARADIGM CORP : Other Events, Financial Statements and Exhibits (form 8-K) AQ
ARADIGM CORP : Other Events (form 8-K) AQ
ARADIGM CORP : Other Events, Financial Statements and Exhibits (form 8-K) AQ
ARADIGM CORP : Other Events (form 8-K) AQ
Aradigm : Announces Sale of Assets to Grifols, S.A. AQ
More press releases

Company Profile

Aradigm Corp is a United States-based company. The Company is an emerging specialty pharmaceutical company focused on the development and commercialization of drugs for the prevention and treatment of severe respiratory diseases. Its inhaled ciprofloxacin formulations are also product candidates for treatment of patients with cystic fibrosis and non-tuberculous mycobacteria, and for the prevention and treatment of high threat and bioterrorism infections, such as inhaled tularemia, pneumonic plague, melioidosis, Q fever and inhaled anthrax.
Sector
Biotechnology & Medical Research
More about the company

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
ARADIGM CORPORATION Stock Aradigm Corporation
-25.81% 702K
MODERNA, INC. Stock Moderna, Inc.
+33.63% 50.85B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-0.09% 42.82B
LONZA GROUP AG Stock Lonza Group AG
+49.62% 42.03B
CELLTRION, INC. Stock Celltrion, Inc.
-4.96% 29.55B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+11.18% 26.11B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-21.95% 19.13B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+8.61% 13.05B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+28.31% 12.16B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+24.73% 12.08B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. ARDMQ Stock